We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Biologics Legislation In The 111th Congress

Law360 (April 6, 2009, 12:00 AM EDT) -- Two bills have been introduced in the House that aim to create an FDA approval process for follow-on biologics similar to that established for generic drugs in the Hatch-Waxman Act of 1984.

The first bill, H.R. 1427, the “Promoting Innovation and Access to Life-Saving Medicine Act”, outlines an approval process that is highly favorable to follow-on biologic companies, whereas the second bill, H.R. 1548, the “Pathway for Biosimilars Act”, stakes out a position somewhat more favorable to the innovator biologics industry. A new law could take...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.